Chimerix (NASDAQ:CMRX - Get Free Report) is set to release its earnings data before the market opens on Thursday, November 7th. Analysts expect Chimerix to post earnings of ($0.24) per share for the quarter. Individual that are interested in participating in the company's earnings conference call can do so using this link.
Chimerix (NASDAQ:CMRX - Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.23). The firm had revenue of $0.13 million for the quarter, compared to the consensus estimate of $1.26 million. During the same quarter in the previous year, the business posted ($0.21) EPS. On average, analysts expect Chimerix to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Chimerix Stock Performance
Shares of NASDAQ:CMRX traded up $0.02 during trading on Friday, reaching $0.99. The stock had a trading volume of 208,057 shares, compared to its average volume of 353,120. Chimerix has a 52 week low of $0.75 and a 52 week high of $1.30. The firm's fifty day moving average is $0.90 and its 200 day moving average is $0.91. The stock has a market cap of $88.74 million, a price-to-earnings ratio of -1.04 and a beta of 1.12.
Analyst Ratings Changes
A number of brokerages have weighed in on CMRX. StockNews.com upgraded Chimerix from a "sell" rating to a "hold" rating in a report on Wednesday, August 21st. Wedbush reaffirmed an "outperform" rating and set a $6.00 target price on shares of Chimerix in a research note on Tuesday, August 13th. Finally, HC Wainwright reiterated a "buy" rating and issued a $11.00 target price on shares of Chimerix in a report on Wednesday, August 14th.
Get Our Latest Report on Chimerix
Chimerix Company Profile
(
Get Free Report)
Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.
Read More
Before you consider Chimerix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chimerix wasn't on the list.
While Chimerix currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
